

The fund was up 6.8% in the fourth quarter, outperforming its benchmark of the FTSE World Index up 3.8%. It has delivered a return of 37.0% over the last year, outperforming the benchmark (up 23.5%) and has delivered 6.8% pa annualised return over the last five years.

### Economic backdrop

Global economic activity has slowed due to increased US tariffs and persistent uncertainty surrounding a US foreign-policy stance that has shifted from broadly chaotic and aggressive to persistently disruptive. Financial conditions, which tightened meaningfully in the immediate aftermath of the April US tariff announcements, have since loosened, driven by a sharp rise in asset prices and lower short-term interest rates.

In the US, erratic government policy continues to result in subdued consumer and business sentiment and reduced investment, although the decline in business investment has been less severe than expected due to robust AI-driven spending. The US labour market is softening despite sharply lower supply from immigration, as companies delay hiring amid tariff uncertainty and AI-driven change. This is depressing sentiment, exacerbating skills mismatches and leading to more cautious workforce planning. Consequently, looking through near-term moderate improvements in growth, driven by fading tariff impacts, the recovery from the government shutdown and front-loaded fiscal stimulus, underlying US economic growth appears to be softening from its previously robust pace.

China's nominal economic growth has been weak due to ongoing deflation, consumer scarring from the pandemic and the property market correction. This is reflected in low confidence, negative wealth effects and elevated precautionary savings. More aggressive monetary and fiscal stimulus and targeted structural state interventions have not yet succeeded in improving Chinese consumer confidence. Export activity has been unexpectedly resilient, with strong growth to emerging markets offsetting the adverse effects of US tariffs. It is expected to remain robust as China's cost competitiveness improves.

Europe's economy, which has been stagnating in part from its export link to a weak manufacturing sector in China, will start to benefit from higher domestic fiscal stimulus - particularly in Germany. Japan's economy is expected to continue to experience a steady, domestically driven expansion supported by ongoing labour market strengthening and gradually improving business investment.

### Markets review

Global markets were positive in the fourth quarter, up 3.2% in US dollars. The UK and Japan were the strongest contributors, gaining 6.8% and 6.0% respectively. Emerging markets performed slightly better over the quarter, up 4.8%, led by strong gains in South Korea (up 24.7%) and South Africa (up 14.2%). Overall, 2025 was a very positive year for global equity markets, which rose 21.6%, with emerging markets significantly outperforming, up 34.4%.

### Fund performance and positioning

Notable positive contributors included Albermarle, Micron, Bayer and Roche Holdings. JD.Com, JD Sports and PVH Corp were the main detractors. We remain overweight in European equities and substantially underweight in US equities relative to our benchmark. We have maintained our positioning in high-quality cyclical companies as we believe that share price levels are still low relative to their long-term prospects, and they should provide very attractive forward-looking returns.

### Stock snapshot

**Zoetis** is the world's largest animal health company, with a dominant, high-margin portfolio of vaccines and medicines spanning companion animals and livestock. Originally part of Pfizer, the business has established itself as the clear market leader, consistently capturing a disproportionate share of industry growth.

Approximately 70% of revenue is generated from companion animals, a segment supported by strong long-term tailwinds, including rising pet ownership, the increasing "humanisation" of domestic pets, premiumisation of care and longer pet lifespans.

Zoetis is well positioned to benefit from these trends through leadership in important therapeutic categories such as parasiticides, dermatology, pain management and vaccines. These markets feature growing demand and strong pricing power, reinforced by close veterinarian relationships and a large direct sales force. Ongoing innovation remains a key differentiator, with a robust pipeline supporting organic growth and lifecycle extension of established franchises.

The animal pharmaceutical industry differs meaningfully from human pharmaceuticals, with much shorter development timelines, significantly lower R&D costs and a four-times higher success rate. Pricing is largely market-based, determined by vets and pet owners rather than government or insurance reimbursement systems, enabling Zoetis to commercialise products efficiently, while earning attractive returns with lower structural risk. Recent share price weakness has created an opportunity to add this high-quality, defensive growth business to our global funds.

**Disclaimer:** The Camissa Islamic Global Equity Fund is a sub-fund of Camissa Global Asset Management ICAV. This Fund is managed by Sanlam Asset Management (Ireland) Limited. The Fund and the Manager are authorised in Ireland and regulated by the Central Bank of Ireland.

**Fees and performance:** Unit trusts are generally medium- to long-term investments. The value of units will fluctuate, and past performance should not be used as a guide for future performance. Camissa does not provide any guarantee either with respect to the capital or the return of the portfolio(s). In addition, macroeconomic, political, foreign exchange, tax and settlement risks may apply. However, our robust investment process takes these factors into account. Unit trusts are traded at ruling prices and can engage in scrip lending and borrowing. Exchange rate movements, where applicable, may affect the value of underlying investments. Different classes of units may apply and are subject to different fees and charges. Camissa has the right to close the portfolio to new investors to manage it more effectively in accordance with its mandate.

**Additional information:** Please read the key investor information in conjunction with the supplement of the fund and the fund prospectus.